The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
MiR‐34a attenuates paclitaxel‐resistance of hormone‐refractory prostate cancer PC3 cells through direct and indirect mechanisms
Abstract
BACKGROUND: Patients with hormone‐refractory prostate cancer are treated with taxane drugs, but eventually become drug resistant. We aimed to elucidate the molecular mechanisms underlying paclitaxel resistance of hormone‐refractory prostate cancer with a special focus on the roles of miR‐34a and SIRT1. METHODS: Paclitaxel‐resistant cells (PC3PR) were generated from hormone‐refractory PC3 cells. The expression levels of mRNA and miRNA were determined by reverse transcriptase PCR and those of protein were by Western blot analysis. Transfection of miRNA precursor or siRNA was performed using the liposome‐mediated method. RESULTS: MiR‐34a over‐expression and SIRT1 knockdown attenuated paclitaxel resistance of PC3PR cells. MiR‐34a expression was reduced in PC3PR cells compared with PC3 cells, while the expression levels of HuR and Bcl2 as well as SIRT1 were elevated in PC3PR cells. Luciferase reporter assays revealed that both SIRT1 3′‐UTR and promoter activities were higher in PC3PR cells than in PC3 cells. Introduction of miR‐34a precursor into PC3PR cells resulted in decreases in HuR, Bcl2, and SIRT1 expression and inhibition of the SIRT1 3′‐UTR activity. HuR knockdown reduced SIRT1 and Bcl2 expression. These results suggest that miR‐34a not only directly but also indirectly via regulating HuR expression acts on the 3′‐UTR of SIRT1 and Bcl2 mRNAs, thereby controlling their expression. Thus, in PC3PR cells, reduced expression of miR‐34a confers paclitaxel resistance via up‐regulating SIRT1 and Bcl2 expression. CONCLUSIONS: MiR‐34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance, all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone‐refractory prostate cancer. Prostate 70: 1501–1512, 2010. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
Wang, X., Liu, P., Zhu, H., Xu, Y., Ma, C., Dai, X., Huang, L., Liu, Y., Zhang, L., & Qin, C. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.08.006 · Cited by 271
Cited by
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Kasinski, A. L., & Slack, F. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3166 · Cited by 936
miR-34 – a microRNA replacement therapy is headed to the clinic
Bader, A. G. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00120 · Cited by 728
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
Mir-34: A New Weapon Against Cancer?
Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.47 · Cited by 498
MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review
Catto, J. W. F., Alcaraz, A., Bjartell, A. S., De Vere White, R., Evans, C. P., Fussel, S., Hamdy, F. C., Kallioniemi, O., Mengual, L., Schlomm, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.01.044 · Cited by 469
Metadata
- Authors
- Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., & Ito, M.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2010-08-23
- Volume
- 70
- Issue
- 14
- Pages
- 1501-1512
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2013073866
- Cited by
- 205
- References
- 3
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MiR‐34a attenuates paclitaxel‐resistance of hormone‐refractory prostate cancer PC3 cells through direct and indirect mechanisms. https://app.cochat.ai/papers/10.1002/pros.21185
- The paper
- Kojima, K., Fujita, Y., Nozawa, Y., Deguchi, T., & Ito, M. (2010). MiR‐34a attenuates paclitaxel‐resistance of hormone‐refractory prostate cancer PC3 cells through direct and indirect mechanisms. The Prostate. https://doi.org/10.1002/pros.21185
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.